Everything You Were Told About Menopause Was Wrong — The 2025 Update

Published: March 22, 2026  ·  Last updated: April 28, 2026

If you're between 45 and 60 and have asked your doctor about hormone therapy, you have probably heard some version of: it causes breast cancer, it causes strokes, it causes heart attacks, the risks outweigh the benefits. That summary has been wrong for most women for most of two decades. The FDA just acknowledged it.

In November 2025, the FDA initiated removal of the black box warnings from most menopausal hormone therapy products — the boxed labels that had warned of breast cancer, stroke, heart attack, and dementia risk since 2003. The warnings were a response to the 2002 Women's Health Initiative trial, which was the largest study ever done on hormone therapy. The trial's findings were correct. The way they were communicated, applied, and remembered was not.

What the WHI Actually Found — and What It Didn't

The Women's Health Initiative enrolled women with an average age of 63 — well past the typical menopause transition. The combined estrogen-plus-progestin arm of the study found a small absolute increase in breast cancer, stroke, and heart attack risk, and the trial was halted early in 2002. Those findings drove the FDA to add the boxed warning.

What got lost: the WHI did not study younger women starting hormone therapy near the time of menopause. Subsequent re-analyses, including those summarized by Harvard Health, found that the cardiovascular harms clustered in women who started therapy more than 10 years after menopause. In women within 10 years of menopause, hormone therapy did not produce the same risk pattern — and in some analyses, it appeared cardioprotective.

The estrogen-only arm (for women without a uterus) actually showed a modest reduction in breast cancer risk — the opposite of the headline. That nuance never made it into the public conversation.

What the FDA Actually Changed in 2025

Per the HHS fact sheet on the November 2025 announcement, the FDA initiated removal of references to cardiovascular disease, breast cancer, and probable dementia from the boxed warnings on menopausal hormone therapy product labels. The boxed warning was also removed from low-dose vaginal estrogen products used for genitourinary symptoms.

The FDA kept the warning of endometrial cancer risk on systemic estrogen products taken without progestin in women with a uterus — that risk is established and clinically meaningful. The agency emphasized that label changes don't mean hormone therapy is right for every woman; they mean the labels now reflect the risk profile actually supported by 22 years of follow-up data.

The Menopause Society's response was that the change 'restores nuance' — allowing doctors and patients to have honest, individualized conversations about whether hormone therapy is appropriate, rather than starting every conversation with a black box.

Who Hormone Therapy Is and Isn't For

The Menopause Society's hormone therapy position statement summarizes the case clearly: for healthy women under 60, or within 10 years of menopause onset, who have moderate to severe vasomotor symptoms (hot flashes, night sweats), or genitourinary symptoms, or are at elevated risk of bone loss, the benefits of appropriately selected hormone therapy generally outweigh the risks.

Hormone therapy is not appropriate for women with a personal history of breast cancer, undiagnosed vaginal bleeding, active liver disease, or a history of certain blood clots or strokes. Risk goes up when therapy is initiated more than 10 years after menopause or after age 60. These are individualized decisions, not one-size-fits-all.

The treatment options have also expanded. Transdermal estrogen (patches, gels) appears to carry a lower clot risk than oral estrogen. Bioidentical hormones are FDA-approved when prescribed and dispensed through licensed pharmacies — but compounded bioidenticals from custom pharmacies are not FDA-evaluated and should be approached carefully.

Why This Matters Now

Roughly two million women enter menopause in the US every year. For about 75 percent of them, vasomotor symptoms — hot flashes and night sweats — interfere with sleep, work, mood, and quality of life. For roughly 20 to 25 percent, the symptoms are severe enough to be disabling. The 2003 boxed warning meant that effective treatment was something doctors and patients had to talk around, not toward.

The 2025 label change doesn't make hormone therapy automatically right for any individual woman — it changes the starting position of the conversation. Women in the right age and risk window can now discuss hormone therapy with their doctors without the label itself doing the rejecting.

If your doctor still defaults to 'we don't recommend hormone therapy,' it's a reasonable question to ask whether that recommendation reflects current evidence, your specific risk profile, or a 22-year-old habit.

To your health,

Ageless CoachTM

Age Strong. Live Long.

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reading this article does not create a provider-patient relationship. Always consult your physician or qualified healthcare provider before making changes to your diet, exercise, or health routine. Ageless Coach is not liable for any actions taken based on this information.